A resolution designating July 16, 2025, as "Glioblastoma Awareness Day".
This bill is a Senate resolution designating July 16, 2025, as “Glioblastoma Awareness Day.” It is a symbolic, nonbinding expression from the Senate intended to raise public awareness about glioblastoma, honor those affected by the disease, and highlight the need for better treatments and ongoing research. The resolution emphasizes the severity of glioblastoma (the most common and deadly primary malignant brain tumor), notes the importance of biomarker testing for diagnosis and treatment, and endorses collaboration among government, private industry, and nonprofit organizations to advance glioblastoma research and therapies, including continued support for the Glioblastoma Therapeutics Network (GTN) and other brain tumor resources. The bill does not create new programs or authorize spending. Instead, it publicly recognizes the burden of glioblastoma, encourages awareness and support for patients and caregivers, and calls for continued investment and collaboration to accelerate advances in treatment and quality of life for those affected.
Key Points
- 1Designation: Designates July 16, 2025, as “Glioblastoma Awareness Day.”
- 2Public awareness and honors: Encourages increased public awareness and honors individuals who have died from glioblastoma or are living with the disease.
- 3Treatment advancement: Supports efforts to develop better treatments to improve long-term prognosis and quality of life for patients.
- 4Biomarker testing: Recognizes the importance of molecular biomarker testing for diagnosis and treatment decisions in glioblastoma.
- 5Collaborative research: Urges a collaborative approach to brain tumor research among government, private sector, and nonprofit organizations.
- 6Continued investment: Encourages ongoing investments in glioblastoma research and treatments, including through the Glioblastoma Therapeutics Network and other brain tumor resources.